All In Biotech

Drug Trial Radar · NCT07756957

Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne

A Phase 1/2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of an Acne mRNA Vaccine Candidate in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

410

Planned (sponsor's estimate)

Start

Oct 14, 2026

Primary completion

Jul 19, 2028

Study completion Feb 19, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety profile of intramuscular injections of the Acne mRNA vaccine at 3 dose levels compared with placebo in 12 to 17 years old participants with moderate to severe acne. An early safety data review (ESDR) will be conducted after each subcohort has completed an injection round; enrollment of the next higher dose level subcohort or progression of a subcohort to the subsequent injection round will only proceed if no safety concerns are identified. This sequential process will allow a cautious approach to vaccine injection in the adolescent population. Study details are as follows: * Before being enrolled in the study, participants complete a 4-week (ie, 1-month) screening period during which they will be called over the telephone approximately in the middle of the screening period to check they are not using prohibited medications and to remind them about the facial hygiene requirements. * Once the screening period has been completed, the study duration will be up to 13 months for each participant * Participants will be invited to a long-term extension study through a separate protocol.

Conditions

  • Acne

Interventions

  • Acne mRNA (messenger ribonucleic acid) vaccineBiological

    IM injection

  • PlaceboBiological

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Unsolicited systemic AEs (Adverse Events)Time frame: 30 minutes after each injection
  2. Solicited injection site and systemic adverse reactionsTime frame: 8 days, including the day of each injection
  3. Unsolicited AEsTime frame: 28 days, including the day of each injection
  4. SAEs (Serious Adverse Events), MAAEs (Medically Attended Adverse Event), AESIs (Adverse Event of Special Interest) and AEs (Adverse Events) leading to study discontinuationTime frame: Up to 2 months after last injection
  5. Out-of-range biological test results (including shift from baseline values)Time frame: Within 8 days after each injection, including the day of injection

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 1240001

    Edmonton, Alberta, Canada · Recruiting

  • Investigational Site Number : 1240013

    Edmonton, Alberta, Canada · Recruiting

  • Investigational Site Number : 1240009

    Vancouver, British Columbia, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.